Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by SGS Life Sciences

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sarconeos

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO101

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biophytis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 08, 2020

            Details:

            French biotech firm Biophytis will assess its Sarconeos (BIO101) drug as a treatment for respiratory failure caused by Covid-19 after partnering with contract research organisation (CRO) SGS.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sarconeos

            Therapeutic Area: Infections and Infectious Diseases Product Name: BIO101

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Recipient: Biophytis

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 01, 2020

            Details:

            This pivotal, international clinical trial will be conducted in two parts, the first of which has the objective to assess treatment safety and provide an indication of activity of Sarconeos, in 50 hospitalized COVID-19 patients suffering from acute respiratory deficiency.